Ligand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall Street stocks close lower on higher Treasury yields, rate expectations
- Powell says recent inflation data point to need to keep rates higher for longer
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
Retrophin (RTRX) PT Raised to $40 at BMO Capital
September 7, 2016 4:14 PM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $40.00 (from $28.00) and increase the probability of success for Sparsentan to 45% from 25%, following positive Phase II DUET data.
Kim commented, "While we model an accelerated... More
Retrophin (RTRX) PT Raised to $32 at Leerink Partners Following Clear Efficacy from Sparsentan
September 7, 2016 12:54 PM EDTLeerink Partners analyst Joseph Schwatz reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $32.00 (from $27.00) after the company announced positive top-line results for Phase 2b DUET study of sparsentan in focal segmental glomerulosclerosis (FSGS) this morning and they spoke with... More
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
September 7, 2016 11:00 AM EDTRoth Capital boosts its price target on Buy-rated Ligand Pharmaceuticals (Nasdaq: LGND) from $149 to $151 after the company announced positive data from the sparsentan Phase II study in FSGS patients.
Analyst Joseph Pantginis commented today, This is an important win for RTRX/LGND and management indicated that efficacy for sparsentan... More
Ligand Pharma (LGND) Gains After Retrophin (RTRX) Announces Positive Sparsentan Phase 2 Data
September 7, 2016 7:40 AM EDTLigand Pharma (NASDAQ: LGND) gained Wednesday after Retrophin (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of FSGS.
Retrophin previously secured a license to sparsentan from Ligand Pharmaceuticals and Bristol-Myers Squibb Company.
... More
Deutsche Bank Upgrades Ligand Pharma (LGND) to Hold
September 7, 2016 7:20 AM EDTDeutsche Bank upgraded Ligand Pharma (NASDAQ: LGND) from Sell to Hold with a price target of $105.00 (from $110.00). Analyst Gregg Gilbert said he sees more balanced risk/reward.
The analyst explained, "When we lowered our rating on LGND shares from Hold to Sell on... More
Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'
September 7, 2016 6:53 AM EDTRoth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $149 price target today and offers to remind investors about catalysts coming up this month, which includes the
Phase IIb sparsentan data in FSGS patients being developed by partner Retrophin (Nasdaq:... More
